{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '16.', 'PUBLICATIONS', 'As described in Section 13.2, all protocol- and amendment-related information, with the', 'exception of the information provided by Amgen on public registry websites, is considered', 'Amgen confidential information and is not to be used in any publications. Amgen protocol-', 'related information proposed for use in a publication must be submitted to Amgen for review and', 'approval, and should not be utilized in a publication without express written approval from', 'Amgen, or as described in the Clinical Trial Agreement.', 'Amgen will ensure Amgen-sponsored studies are considered for publication in the scientific', 'literature in a peer-reviewed journal, irrespective of the results. At a minimum, this applies to', 'results from all Phase 3 clinical studies, and any other study results of significant medical', 'importance. This also includes results relating to investigational medicines whose development', 'programs have been discontinued.', 'Study results may also be presented at one or more medical congresses, and may be used for', 'scientific exchange and teaching purposes. Additionally, this study and its results may be', 'submitted for inclusion in all appropriate health authority study registries, as well as publication', 'on health authority study registry websites, as required by local health authority regulations.', 'Eligibility for authorship, will be in alignment with ICMJE authorship criteria and be based on', 'several considerations, including, but not limited to, contribution to protocol development, study', 'recruitment, data quality, participation in data analysis, and contribution to abstract, presentation,', 'and/or publication development.', 'Confidential and Proprietary', '70', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '17.', 'REFERENCES', 'EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life.', 'Health Policy. 990;16(3):199-208.', 'Feuerhahn J, Blome C, Radtke M, Augustin M. Validation of the patient benefit index for the', 'assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res.', '2012;304(6):433-41.', 'Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for', 'routine clinical use. Clin Exp Dermatol. 1994;19(3):210-6', 'Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica.', '1978;157(4):238-44.', 'Gottlieb AB. Psoriasis - Enhanced epidermal differentiation and reduced cell-mediated', 'inflammation are unexpected outcomes. Dis Manag Clin Outcome. 1998; 1 (6): 195-202.', 'Leonardi C, Sobell J, Sofen H, Krell J. Phase IV study to evaluate the safety and efficacy of', 'efalizumab for treatment of hand and foot plaque psoriasis. Poster presented at: 65th Annual', 'Meeting of the American Academy of Dermatology; 2007 Feb 2-6; Washington, DC.', 'Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature.', '2007;445(7130):866-73.', 'Merola JF, Bleakman AP, Gottlieb AB, Menter A, Naegeli AN, Bissonnette R, et al. The Static', \"Physician's Global Assessment of Genitalia: a clinical outcome measure for the severity of\", 'genital psoriasis. J Drugs Dermatol. 2017;16(8):793-9.', 'Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment', 'goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res.', '2011;303(1):1 -10.', 'Naegeli AN, Flood E, Tucker J, Devlen J, Edson-Heredia E. The Worst Itch Numeric Rating', 'Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol.', '2015;54(6):715-22.', 'Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.', 'NHLBI Obesity Education Initiative. The practical guide: identification, evaluation, and', 'treatment of overweight and obesity in adults. [cited 2018 Apr 04]. Available from:', 'http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf.', 'Reilly Associates. Work Productivity and Activity Impairment Questionnaire: Psoriasis', '(WPAI:PSO). 2012. [cited 2018 May 01]. Available from:', 'http://www.reillyassociates.net/WPAI_References3.html. Accessed May 01,.', 'Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis.', 'J Am Acad Dermatol. 2003;49(2):206-12.', 'Walsh JA, McFadden M, Woodcock J, Clegg DO, Helliwell P, Dommasch E, et al. Product of', 'the Physician Global Assessment and body surface area: a simple static measure of psoriasis', 'severity in a longitudinal cohort. J Am Acad Dermatol. 2013;69(6):931-7.', 'Confidential and Proprietary', '71', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}